KDR and Hypertension: Grade ≥3 TRAEs attributed to VEGFR TKI class effects were reported in 46% and 55% of patients treated with tivozanib and sorafenib, respectively, with the most common (>5% incidence in either arm) being hypertension, diarrhea, fatigue, asthenia, rash, and palmar-plantar erythrodysesthesia (Supplementary Table S3).